Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy

Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Olga Nikolaevna Tkacheva, Irina Mikhailovna Novikova, Natalya Viktorovna Sharashkina, Khyadi Magometovna Torshkhoeva, Nadezhda Konstantinovna Runikhina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	diabetic neuropathy dislipidemia fenofibrate Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/aa80eabb72264d718010560156b4bb37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa80eabb72264d718010560156b4bb37
record_format	dspace
spelling	oai:doaj.org-article:aa80eabb72264d718010560156b4bb372021-11-14T09:00:14ZEffects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy2072-03512072-037810.14341/2072-0351-6014https://doaj.org/article/aa80eabb72264d718010560156b4bb372010-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6014https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy,it suggests the possibility to treat this disorder with fenofibrate.Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensiveand glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when thesought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability;QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound.Olga Nikolaevna TkachevaIrina Mikhailovna NovikovaNatalya Viktorovna SharashkinaKhyadi Magometovna TorshkhoevaNadezhda Konstantinovna RunikhinaEndocrinology Research Centrearticlediabetic neuropathydislipidemiafenofibrateNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 1, Pp 33-39 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetic neuropathy dislipidemia fenofibrate Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetic neuropathy dislipidemia fenofibrate Nutritional diseases. Deficiency diseases RC620-627 Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
description	Diabetic neuropathy is a severe complication of diabetes mellitus (DM) that considerably worsens the patients quality of life and reduces life expectancy.The FIELD study for the first time demonstrated the ability of fenofibrate to prevent macro- and microvacular complications in patientswith DM2 regardless of glycated hemoglobin level and dyslipidemia at the early stage of the disease. Neuropathy being a manifestation of microangiopathy,it suggests the possibility to treat this disorder with fenofibrate.Aim. To study effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy. Materials and methods. The present study included 73 patients with DM2 randomized into 2 groups to receive standard therapy (antihypertensiveand glucose control, statins) or fenofibrate (Tricor 145 mg, Solvay Pharma) in addition to the standard treatment. Results. Positive effect of fenofibrate on autonomous and peripheral neuropathy was apparent within 6 months after the onset of therapy when thesought parameters of AP, glycemia, and lipid spectrum were achieved. Fenofibrate improved cardiovascular function, reduced cardiac rhythm variability;QT length and dispersion, pain and paresthesia thereby enhancing quality of life and preventing cardiovascular catastrophes including death. Conclusion. It is concluded that supplementation of standard therapy of DM with fenofibrate is both safe and pathogenetically sound.
format	article
author	Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina
author_facet	Olga Nikolaevna Tkacheva Irina Mikhailovna Novikova Natalya Viktorovna Sharashkina Khyadi Magometovna Torshkhoeva Nadezhda Konstantinovna Runikhina
author_sort	Olga Nikolaevna Tkacheva
title	Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
title_short	Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
title_full	Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
title_fullStr	Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
title_full_unstemmed	Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
title_sort	effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/aa80eabb72264d718010560156b4bb37
work_keys_str_mv	AT olganikolaevnatkacheva effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT irinamikhailovnanovikova effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT natalyaviktorovnasharashkina effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT khyadimagometovnatorshkhoeva effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy AT nadezhdakonstantinovnarunikhina effectsoffenofibrateinpatientswithtype2diabetesmellituscomplicatedbydiabeticneuropathy
_version_	1718429673868754944

Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy

Ejemplares similares